Five investigational immunotherapies targeting a range of types of cancers.
Advaxis’ lead Lm Technology™ immunotherapies axalimogene filolisbac and ADXS-DUAL target HPV-associated cancers and are in clinical trials for four potential indications.
ADXS-PSA is under investigation for targeting the prostate-specific antigen (PSA) associated with prostate cancer and is in clinical development both as a monotherapy and in combination with immune checkpoint inhibitors for the treatments of metastatic castration-resistant prostate cancer (mCRPC).
Advaxis is developing ADXS-HER2 to target human epidermal growth factor receptor 2 (HER2)-expressing cancers. HER2 is expressed in certain solid-tumor cancers, including some breast, gastric, and esophageal cancers and osteosarcoma.
Taking advantage of recent advances in genome sequencing with the capacity to target all of a patient’s immunogenic cancer neoepitopes, Advaxis’ has two candidates utilizing neoepitopes:
ADXS-NEO (in partnership with Amgen)